-
DiDi Advances Robotaxi Operations in China with New R2 Vehicle and Expanded Safety Infrastructure
-
Smart Car Seats Tested: Do Sensors and Apps Actually Improve Safety?
-
XPENG Launches Two New Models in UK; Pony.ai Robotaxi Enters Pilot
-
MedMira Receives U.S. FDA Breakthrough Device Designation for Its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test
-
Pivotree Announces Third Quarter 2026 Results
-
Ur-Energy Commences Baseline Study Fieldwork; Nears Completion of Technical Report at Lost Soldier Uranium Project, Wyoming
-
ImageWorks Display Advances Whole-Store Solutions with a Re-Imagined Planniq Strong and Planniq Chill
-
Razavi Law Group Partners with Chapman University to Prepare the Next Generation of Attorneys
-
Broad Clinical Labs Drives Strong Digital Engagement by Connecting Customers with Published Research Through Bioz
-
PRAAMS AI Co-Investor Now Covers 400,000+ Global Instruments, With Responses From 3 Seconds, Cost From US$0.01, and Scalability to Millions of Users
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 17
-
Driving Global Innovation - GTDC Summit APJ Underscores Distribution's Transformative Power
-
Pilot-Founded Solara Global Jet Offers Charter, Leases and Air Cargo Nationwide and Overseas
-
How to Turn Your Garage into Usable Living Space
-
Three Inaugural CombatX Champions Crowned at BRAVE CF Road to BRAVE Event in Hungary
-
French Economy Shrinks 0.1% as Consumer Confidence Slumps
-
China's Factory Activity Contracts as Export Orders Weaken
-
Wall Street Ends Turbulent Week Higher Despite Inflation and AI Jitters
-
US Retail Sales and Fed Minutes Set Up a Critical Test for Consumers
-
Kansas City Fed Chief Says Inflation Is Still Running Too Hot
-
Oil Heads for Second Weekly Loss as Supply Surplus Emerges
-
Luxury Skincare Brand Faces Backlash Over Futurist Manifesto Aesthetic
-
Asian Markets Slide as AI Concerns Hit Chip Stocks
-
Brazil Faces Debt and Inflation Test as Lula Prepares Fourth Term
-
Canada Signals Openness to Chinese Automakers if US Trade Talks Fail
-
Canada Expands Asian Trade Push as US Negotiations Resume
-
US Mortgage Rate Falls for Fourth Week but Remains Above 7%
-
US Jobless Claims Rise to 200,000 but Layoffs Remain Historically Low
-
Italy Raises 2026 Growth View but Warns Energy Will Keep Inflation High
-
Godzilla Minus Zero Review: Takashi Yamazaki’s Anti-Nuclear Allegory
-
Euro-Area Growth Slows to 0.4% While Employment Stalls
-
DA Demands No-Work-No-Pay for Striking Municipal Workers in Coalition Talks
-
UK Economy Grows 0.7% in Third Quarter as Services Lead Expansion
-
US Wholesale Inflation Eases Monthly but Hits a Four-Year Annual High
-
India's Retail Inflation Reaches 6.09% as Food Prices Accelerate
Radius Pharmaceuticals Announces Victory in Patent Infringement Case Against Orbicular Pharmaceutical Technologies for Osteoporosis Treatment TYMLOS(R)
BOSTON, MA / ACCESS Newswire / July 31, 2025 / Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceutical company focused on bone health and related areas, announced today that the U.S. District Court for the District of Massachusetts has ruled in favor of Radius and co-plaintiff Ipsen Pharma S.A.S. ("Ipsen") in a patent infringement suit against Orbicular Pharmaceutical Technologies Private Ltd. ("Orbicular") for their proposed generic for TYMLOS® (abaloparatide) for osteoporosis. Radius and Ipsen prevailed, and the court upheld the validity of all five TYMLOS® patents asserted, in which the latest to expire will remain in effect through April 30, 2038.
The suit was brought by Radius and Ipsen in September 2022 alleging patent infringement by Orbicular in their attempt to seek FDA approval to market a generic abaloparatide product. Radius asserted that Orbicular's proposed generic product would infringe five patents held by Radius.
The favorable ruling reinforces the strength of the TYMLOS® patent portfolio and represents an important win for Radius.
About Radius:
Radius is a global biopharmaceutical company dedicated to transforming the future for underserved, global patient populations in bone health and related areas. Radius' lead product, TYMLOS® (abaloparatide) injection, a parathyroid hormone related peptide, is approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women and men with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture) or patients who have failed or are intolerant to other available osteoporosis therapy. Abaloparatide is supplied as a single-patient multi-use prefilled pen designed to subcutaneously administer 80 micrograms per dose over a 30-day period. For additional information, please visit www.TYMLOS.com.
Contact:
Al Medwar: Senior Vice President, Business and Corporate Development, Radius
Email: [email protected]
SOURCE: Radius Health
View the original press release on ACCESS Newswire
W.Morales--AT